Skip to main content

Another RA-backed biotech hits Nasdaq as public market stirs again after a bruising first quarter

Submitted by admin on
snippet

California’s AN2 Therapeutics has been on a roll recently.

The lung disease biotech raised $80 million in a Series B back in January, announcing it in the company’s first press release since its series A round in 2019. At the time, big backers included RA Capital Management, a VC firm that’s shown a penchant for helping biotechs make quick jumps to the public market.

Source
Endpoints

With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market

Submitted by admin on
snippet

Two biotechs are braving the roiling financial markets to raise money for clinical trials. AN2 Therapeutics is preparing for a pivotal test of its boron-based drug candidate for a rare, chronic lung disease. Okyo Pharma also filed IPO paperwork as it looks to advance to the clinic with its dry eye disease drug.

Source
MedCity News

Bayer, Boston academics form joint lab to research lung disease

Submitted by admin on
snippet

Bayer, Brigham and Women's Hospital (BWH) and Massachusetts General Hospital have teamed up to work on treatments for chronic lung diseases. They will work out of a joint lab in Boston that will receive more than $30 million over the next five years.

Source
Fierce Biotech

CureVac and Yale Team Up for mRNA-Based Lung Therapies

Submitted by admin on
snippet

Under the terms of the deal with Yale University, Yale researchers led by Geoff Chupp will conduct discovery research on targets associated with pulmonary diseases, then turn over the candidates to CureVac for preclinical and clinical development.

Source
BioSpace